Please use this identifier to cite or link to this item: https://hdl.handle.net/10316/106529
DC FieldValueLanguage
dc.contributor.authorCunha-Oliveira, Teresa-
dc.contributor.authorMontezinho, Liliana-
dc.contributor.authorMendes, Catarina-
dc.contributor.authorFiruzi, Omidreza-
dc.contributor.authorSaso, Luciano-
dc.contributor.authorOliveira, Paulo J.-
dc.contributor.authorSilva, Filomena S. G.-
dc.date.accessioned2023-04-06T10:19:51Z-
dc.date.available2023-04-06T10:19:51Z-
dc.date.issued2020-
dc.identifier.issn1942-0994pt
dc.identifier.issn1942-0900pt
dc.identifier.urihttps://hdl.handle.net/10316/106529-
dc.description.abstractAmyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease or Charcot disease, is a fatal neurodegenerative disease that affects motor neurons (MNs) and leads to death within 2-5 years of diagnosis, without any effective therapy available. Although the pathological mechanisms leading to ALS are still unknown, a wealth of evidence indicates that an excessive reactive oxygen species (ROS) production associated with an inefficient antioxidant defense represents an important pathological feature in ALS. Substantial evidence indicates that oxidative stress (OS) is implicated in the loss of MNs and in mitochondrial dysfunction, contributing decisively to neurodegeneration in ALS. Although the modulation of OS represents a promising approach to protect MNs from degeneration, the fact that several antioxidants with beneficial effects in animal models failed to show any therapeutic benefit in patients raises several questions that should be analyzed. Using specific queries for literature search on PubMed, we review here the role of OS-related mechanisms in ALS, including the involvement of altered mitochondrial function with repercussions in neurodegeneration. We also describe antioxidant compounds that have been mostly tested in preclinical and clinical trials of ALS, also describing their respective mechanisms of action. While the description of OS mechanism in the different mutations identified in ALS has as principal objective to clarify the contribution of OS in ALS, the description of positive and negative outcomes for each antioxidant is aimed at paving the way for novel opportunities for intervention. In conclusion, although antioxidant strategies represent a very promising approach to slow the progression of the disease, it is of utmost need to invest on the characterization of OS profiles representative of each subtype of patient, in order to develop personalized therapies, allowing to understand the characteristics of antioxidants that have beneficial effects on different subtypes of patients.pt
dc.language.isoengpt
dc.publisherHindawipt
dc.relationPTDC/ MED-FAR/29391/2017pt
dc.relationPOCI-01-0145-FEDER-029391pt
dc.relationPTDC/BTM-SAL/29297/2017pt
dc.relationPOCI-01-0145- FEDER-029297pt
dc.relationUIDB/04539/2020pt
dc.rightsopenAccesspt
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt
dc.subject.meshAnimalspt
dc.subject.meshAntioxidantspt
dc.subject.meshDisease Models, Animalpt
dc.subject.meshHumanspt
dc.subject.meshNeuroprotective Agentspt
dc.subject.meshOxidative Stresspt
dc.subject.meshAmyotrophic Lateral Sclerosispt
dc.subject.meshMotor Neuronspt
dc.titleOxidative Stress in Amyotrophic Lateral Sclerosis: Pathophysiology and Opportunities for Pharmacological Interventionpt
dc.typearticle-
degois.publication.firstPage5021694pt
degois.publication.lastPage29pt
degois.publication.titleOxidative Medicine and Cellular Longevitypt
dc.peerreviewedyespt
dc.identifier.doi10.1155/2020/5021694pt
degois.publication.volume2020pt
dc.date.embargo2020-01-01*
uc.date.periodoEmbargo0pt
item.openairetypearticle-
item.cerifentitytypePublications-
item.languageiso639-1en-
item.fulltextCom Texto completo-
item.grantfulltextopen-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
crisitem.author.researchunitCNC - Center for Neuroscience and Cell Biology-
crisitem.author.orcid0000-0002-7382-0339-
crisitem.author.orcid0000-0002-5201-9948-
crisitem.project.grantnoCenter for Innovative Biomedicine and Biotechnology - CIBB-
Appears in Collections:I&D CNC - Artigos em Revistas Internacionais
Show simple item record

Page view(s)

77
checked on Jun 26, 2024

Download(s)

42
checked on Jun 26, 2024

Google ScholarTM

Check

Altmetric

Altmetric


This item is licensed under a Creative Commons License Creative Commons